Related Experiment Video
Updated: Oct 2, 2025
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Azithromycin for Poorly Controlled Asthma in Children: A Randomized Controlled Trial
Jagat Jeevan Ghimire1, Kana Ram Jat1, Jhuma Sankar1
1Division of Pediatric Pulmonology and Intensive Care, Department of Pediatrics, New Delhi, India.
Insights
Adding azithromycin to standard therapy significantly improved asthma control in children. This treatment also reduced asthma exacerbations, offering a new therapeutic option for pediatric asthma management.
Area of Science:
- Pediatric Pulmonology
- Clinical Immunology
- Pharmacology
Background:
- Azithromycin exhibits immunomodulatory properties with known benefits in adult asthma.
- Limited data exist regarding azithromycin's efficacy in managing pediatric asthma.
Purpose of the Study:
- To investigate if oral azithromycin improves asthma control in children with poorly controlled asthma when added to standard therapy.
- To compare asthma control, exacerbations, and relevant clinical markers between azithromycin plus standard therapy and standard therapy alone.
Main Methods:
- An open-label randomized controlled trial involving 120 children (5-15 years) with poorly controlled asthma (Asthma Control Test/Childhood Asthma Control Test score ≤ 19).
- Participants received either azithromycin (10 mg/kg) thrice weekly for 3 months plus standard treatment or standard treatment alone.
- Primary outcome: change in ACT/CACT scores at 3 months; secondary outcomes included GINA guideline adherence, exacerbation rates, spirometry, FENO levels, and side effects.
Main Results:
- Azithromycin group showed significantly higher ACT/CACT scores (21.71 vs 18.33, P < .001) and better GINA-defined asthma control (41/56 vs 10/56, P < .001) at 3 months.
- The azithromycin group experienced fewer exacerbations requiring emergency visits and steroid use (median 0 vs 1, P < .001).
- No significant differences were observed in FENO levels, spirometry, or adverse events between groups.
Conclusions:
- Oral azithromycin, when added to standard care, effectively improves asthma control in children with poorly controlled asthma.
- Azithromycin treatment leads to a significant reduction in asthma exacerbations in this pediatric population.
- Azithromycin represents a promising therapeutic addition for managing difficult-to-control pediatric asthma.
Background:
Azithromycin has immunomodulatory actions, and its beneficial effects have been demonstrated in asthmatic adults. Data on children are limited.
Research Question:
Does the addition of oral azithromycin to standard therapy in children with poorly controlled asthma improve asthma control compared with standard treatment alone?
Study Design And Methods:
This open-label randomized controlled trial included children (5-15 years of age) with poorly controlled asthma defined by Asthma Control Test (ACT) and Childhood Asthma Control Test (CACT) score of ≤ 19. They were randomized to receive azithromycin (10 mg/kg) three times weekly for 3 months along with standard treatment or standard treatment alone. The primary outcome was the ACT and CACT scores at 3 months. Secondary outcomes were asthma control according to Global Initiative for Asthma (GINA) guidelines, the number of exacerbations, change in spirometry parameters, change in fractional exhaled nitric oxide (Feno) level, positive throat swab results, and side effects.
Results:
The trial included 120 children (89 boys; 60 in each group). The mean ± SD age was 9.9 ± 3 years. The baseline parameters were similar between the groups. Mean ± SD ACT and CACT scores (available for 115 children) at 3 months of intervention were 21.71 ± 2.17 vs 18.33 ± 2.19 (P < .001) in the azithromycin and control groups, respectively. The numbers of children with well-controlled asthma according to GINA guidelines were 41 of 56 vs 10 of 56 in the azithromycin and control groups, respectively (P < .001). The median number of exacerbations requiring emergency visit and steroid use were fewer in the azithromycin group: 0 (interquartile range [IQR], 3) vs 1 [IQR, 6]; P < .001). No difference was found in Feno level, spirometry parameters, positive throat swab results, and adverse effects between the groups.
Interpretation:
The use of azithromycin in children with poorly controlled asthma resulted in improved asthma control and reduced exacerbations.
Trial Registry:
Clinical Trials Registry - India; No.: CTRI/2019/06/019727; URL: www.ctri.nic.in.
